Tekmira wins $2.4 million NIH grant

Tekmira Pharmaceuticals (TSX:TKM) and its collaborators at the University of Texas Medical Branch at Galveston, Tex. have received a $2.4 million (U.S.) grant from the U.S. National Institutes of Health to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections using Tekmira’s lipid nanoparticle delivery technology. According to a [...]

Tekmira reports on protection against deadly Ebola virus

Tekmira Pharmaceuticals (TSX:TKM) has published a series of studies in The Lancet demonstrating the ability of an RNA-interference therapeutic using Tekmira’s SNALP lipid nanoparticle delivery technology to protect non-human primates from Ebola virus, a highly contagious and lethal human infectious disease. “These very striking data are the first demonstration that RNAi is efficacious in an [...]